Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8124823 | 0.87 | LTA4H (0.33) | KDM4ETDP1NPC1MAPTL3MBTL1 | |
| SCHEMBL25434076 | 0.74 | CA12 (0.33) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL29366932 | 0.72 | KDM4E (0.40) | KDM4ENPC1MAPTALDH1A1CYP3A4 | |
| SCHEMBL990076 | 0.72 | KDM4E (0.40) | KDM4ENPC1MAPTALDH1A1CYP3A4 | |
| SCHEMBL28806661 | 0.72 | KDM4E (0.40) | KDM4ENPC1MAPTALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL6994200 | 0.70 | ALDH1A1 (0.39) | KDM4ENPC1MAPTALDH1A1CYP3A4 | |
| SCHEMBL15845563 | 0.67 | KDM4E (0.30) | KDM4E | |
| SCHEMBL4576815 | 0.66 | NAPRT (0.34) | KDM4ETDP1MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL6435739 | 0.65 | KDM4E (0.33) | KDM4ETDP1MAPTL3MBTL1CA12 | |
| SCHEMBL9319851 | 0.64 | HPGD (0.37) | KDM4ENPC1MAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | disclosed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-5536702-A | (2-imidazolin-2-yl) fused heteropyridine compounds and use of said compounds as herbicidal agents | AMERICAN CYANAMID CO. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5536839-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5534483-A | (2-imidazolin-2-yl) fused heteropyridine compounds intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534485-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534484-A | (2-imidazolin-2-yl)fused heteropyridine compounds intermediates for the preparation of and use of said compounds and herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5532207-A | CONTROL OF MONO- AND DI-COTYLEDONOUS ANNUAL, PERENNIAL AND AQUATIC PLANTS; PRE- AND POST-EMERGENCE USE | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5510319-A | PYRROLO-2,3-B-PYRIDINYL DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5252538-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KDM4E 4435/4885TDP1 4867/4885NPC1 1133/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | KDM4E 4341/4885TDP1 4739/4885NPC1 714/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | KDM4E 4571/4885TDP1 3605/4885NPC1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.